EphA2 Overexpression Promotes Ovarian Cancer Growth

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2008 Apr 30

PMID 18443431

Citations 40

Authors

Chunhua Lu

Mian M K Shahzad

Hua Wang

Charles N Landen

Seung W Kim

Julie Allen

Alpa M Nick

Nicholas Jennings

Michael S Kinch

Menashe Bar-Eli

Anil K Sood

Affiliations

Soon will be listed here.

Abstract

Background: Silencing EphA2 has been shown to result in anti-tumor efficacy. However, it is not known whether increasing EphA2 expression specifically results in increased tumor growth and progression. We examined the effects of stable EphA2 transfection into poorly invasive ovarian cancer cells with regard to in vitro invasive and in vivo metastatic potential.

Results: In low cell density, EphA2-overexpressing A2780 cells (A2780-EphA2) displayed less cell-cell contact, increased cell-extracellular matrix (ECM) attachment and anchorage-independent cell growth compared to empty vector controls. There was no significant effect on anchorage-dependent cell proliferation, migration or invasion. Increased expression of EphA2 promoted tumor growth and enhanced the metastatic potential in A2780-EphA2 human ovarian cancer xenografts. The overexpression of EphA2 resulted in enhanced microvessel density (MVD), but had no effect on tumor cell proliferation.

Methods: EphA2 gene was introduced into A2780 cells by retroviral infection. The effects of increased EphA2 expression were examined on cellular morphology, and anchorage-dependent and independent cell growth. Furthermore, the effect of EphA2 overexpression on metastatic ability was determined using an orthotopic nude mouse model of ovarian carcinoma.

Conclusions: EphA2 promotes tumor growth by enhancing cell-ECM adhesion, increasing anchorage-independent growth and promoting angiogenesis.

Citing Articles

Leveraging Multi-omics to Disentangle the Complexity of Ovarian Cancer.

Lin S, Nguyen L, McMellen A, Leibowitz M, Davidson N, Spinosa D Mol Diagn Ther. 2024; 29(2):145-151.

PMID: 39557776 DOI: 10.1007/s40291-024-00757-3.

Erythropoietin-induced hepatocyte receptor A2 regulates effect of pyroptosis on gastrointestinal colorectal cancer occurrence and metastasis resistance.

Zhang Y, Shi R, Meng R, Lin S, Zheng M World J Gastrointest Oncol. 2024; 16(9):3781-3797.

PMID: 39350985 PMC: 11438782. DOI: 10.4251/wjgo.v16.i9.3781.

Exploring the potential of EphA2 receptor signaling pathway: a comprehensive review in cancer treatment.

Nehal M, Khatoon J, Akhtar S, Khan M Mol Biol Rep. 2024; 51(1):337.

PMID: 38393520 DOI: 10.1007/s11033-024-09298-8.

Development of an In-House EphA2 ELISA for Human Serum and Measurement of Circulating Levels of EphA2 in Hypertensive Patients with Renal Dysfunction.

Murakoshi M, Iwasawa T, Koshida T, Suzuki Y, Gohda T, Kato K Diagnostics (Basel). 2022; 12(12).

PMID: 36553030 PMC: 9776842. DOI: 10.3390/diagnostics12123023.

in gastrointestinal cancer: Expression, regulation and clinical significance.

Chu L, Huang B, Huang X, Peng Y, Xie J, Xu Y World J Gastrointest Oncol. 2022; 14(5):973-988.

PMID: 35646281 PMC: 9124989. DOI: 10.4251/wjgo.v14.i5.973.

References

Voskoglou-Nomikos T, Pater J, Seymour L . Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 2003; 9(11):4227-39. View

Walker-Daniels J, Coffman K, Azimi M, Rhim J, Bostwick D, Snyder P . Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate. 1999; 41(4):275-80. DOI: 10.1002/(sici)1097-0045(19991201)41:4<275::aid-pros8>3.0.co;2-t. View

Walker-Daniels J, Hess A, Hendrix M, Kinch M . Differential regulation of EphA2 in normal and malignant cells. Am J Pathol. 2003; 162(4):1037-42. PMC: 1851246. DOI: 10.1016/S0002-9440(10)63899-0. View

Flanagan J, Vanderhaeghen P . The ephrins and Eph receptors in neural development. Annu Rev Neurosci. 1998; 21:309-45. DOI: 10.1146/annurev.neuro.21.1.309. View

Lu C, Bonome T, Li Y, Kamat A, Han L, Schmandt R . Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 2007; 67(4):1757-68. DOI: 10.1158/0008-5472.CAN-06-3700. View

Landen C, Kinch M, Sood A . EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets. 2005; 9(6):1179-87. DOI: 10.1517/14728222.9.6.1179. View

Duxbury M, Ito H, Zinner M, Ashley S, Whang E . EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene. 2004; 23(7):1448-56. DOI: 10.1038/sj.onc.1207247. View

Lindberg R, Hunter T . cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol. 1990; 10(12):6316-24. PMC: 362907. DOI: 10.1128/mcb.10.12.6316-6324.1990. View

Domanska-Janik K, Zajac H, ZABLOCKA B . Interrelations between nuclear-factor kappa B activation, glial response and neuronal apoptosis in gerbil hippocampus after ischemia. Acta Neurobiol Exp (Wars). 2001; 61(1):45-51. DOI: 10.55782/ane-2001-1383. View

10.

Brantley-Sieders D, Zhuang G, Hicks D, Fang W, Hwang Y, Cates J . The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 2007; 118(1):64-78. PMC: 2129239. DOI: 10.1172/JCI33154. View

11.

Zelinski D, Zantek N, Stewart J, Irizarry A, Kinch M . EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 2001; 61(5):2301-6. View

12.

Kataoka H, Igarashi H, Kanamori M, Ihara M, Wang J, Wang Y . Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci. 2004; 95(2):136-41. PMC: 11159731. DOI: 10.1111/j.1349-7006.2004.tb03194.x. View

13.

Sulman E, Tang X, Allen C, Biegel J, Pleasure D, Brodeur G . ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics. 1997; 40(2):371-4. DOI: 10.1006/geno.1996.4569. View

14.

Gale N, Holland S, Valenzuela D, Flenniken A, Pan L, Ryan T . Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron. 1996; 17(1):9-19. DOI: 10.1016/s0896-6273(00)80276-7. View

15.

Lu C, Shen Q, DuPre E, Kim H, Hilsenbeck S, Brown P . cFos is critical for MCF-7 breast cancer cell growth. Oncogene. 2005; 24(43):6516-24. DOI: 10.1038/sj.onc.1208905. View

16.

Pejovic T . Genetic changes in ovarian cancer. Ann Med. 1995; 27(1):73-8. DOI: 10.3109/07853899509031940. View

17.

Carter N, Nakamoto T, Hirai H, Hunter T . EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). Nat Cell Biol. 2002; 4(8):565-73. DOI: 10.1038/ncb823. View

18.

Keely P, Parise L, Juliano R . Integrins and GTPases in tumour cell growth, motility and invasion. Trends Cell Biol. 1998; 8(3):101-6. DOI: 10.1016/s0962-8924(97)01219-1. View

19.

ALVAREZ A, Lambers A, Lancaster J, Maxwell G, Ali S, Gumbs C . Allele loss on chromosome 1p36 in epithelial ovarian cancers. Gynecol Oncol. 2001; 82(1):94-8. DOI: 10.1006/gyno.2001.6175. View

20.

Lickliter J, Smith F, Olsson J, Mackwell K, Boyd A . Embryonic stem cells express multiple Eph-subfamily receptor tyrosine kinases. Proc Natl Acad Sci U S A. 1996; 93(1):145-50. PMC: 40195. DOI: 10.1073/pnas.93.1.145. View